Day Traders, Penny Stocks, Stock Options, Futures and Forex

CHERRY HILL, N.J.--(BUSINESS WIRE)--Nuvilex, Inc. (OTC Bulletin Board: NVLX - News), announces today that it has signed a Production Agreement with Clementine Art, Inc. to develop and manufacture safe, all-natural marker inks. Clementine Art is the only children’s art supply company that develops, manufactures, and sells a full line of natural products. In 2009, Clementine Art sold its art supplies in Whole Foods Market stores and directly to consumers through its web site.

Related Quotes
Symbol Price Change
NVLX.OB 0.0320 0.0000


{"s" : "nvlx.ob","k" : "c10,l10,p20,t10","o" : "","j" : ""} Beginning in December 2009, Nuvilex will manufacture colored marker inks that will be used in 4- and 6-color natural marker sets that will be sold by Clementine Art to its existing and new retail outlets throughout the United States. In addition, customers can place orders online at ClementineArt -- Home --. The Production Agreements also facilitates additional research and development by Nuvilex to expand Clementine Art’s marker and new offering product lines. The Company anticipates, based on increasing demand for Clementine Art products, steadily increasing revenues from its newly signed Production Agreement.

“Nuvilex is excited to work with Clementine Art to develop and manufacture marker inks for Clementine’s all-natural markers,” stated Martin Schmieg, President and CEO of Nuvilex. “Clementine is recognized as a market leader in the development of safe, all-natural art products for children, and it brings us great pleasure to assist Clementine in their quest to develop and market products that will satisfy consumer demand for safe, all-natural and eco-friendly art supplies.”

About Clementine Art, Inc.

Clementine Art, Inc. is a natural, children’s art company located in Boulder, CO that encourages the development of the whole child. Clementine art products and packaging set a higher standard for safety and health in children’s products.

About Nuvilex, Inc.

Nuvilex, Inc. is an emerging healthcare consumer products company. The Company’s lead products include: Cinnergen™, which promotes a healthy glucose metabolism; Cinnechol™, designed to help maintain normal cholesterol levels and support normal cardiovascular function; and Infinitink®, a permanent yet more easily removable tattoo ink. The Company’s complete portfolio spans aesthetics, dermatology, environmental and nutraceutical products, all of which are designed to directly or indirectly improve human health. In March 2009, Nuvilex merged with Freedom2 Holdings, Inc., the developer of Infinitink®. In conjunction with the merger, the Company changed its name to Nuvilex, Inc. from eFoodSafety.com. Please visit Nuvilex for additional information on the Company.

BUSINESS SUMMARY
Nuvilex Inc., through its subsidiaries, engages in the research, development, and marketing of nutraceutical products in the United States and internationally. It has researched and developed a range of whole foods and nutraceutical products to help improve various health conditions, including glucose metabolism, scarring, acne, cholesterol, common cold, influenza, and other known pathogens, such as staphylococcus and streptococcus. The company’s lead product includes Cinnergen, a liquid whole food nutritional supplement that regulates blood sugar levels in Type II diabetics. It also offers Citroxin, a surface cleaner and an antiviral composition against swine influenza virus and avian influenza viruses; Cinnechol, a nutritional supplement to maintain normal cholesterol levels, as well as to support normal cardiovascular function; Cyclesurface3 cosmetics, a lipophilic surface treatment technology that is used to improve the dispersion of pigments in aqueous and organic materials; and Infinitink, a removable tattoo ink. In addition, the company provides Last Shot Hangover Remedy, a liquid nutritional supplement to help the body combat symptoms that are associated with alcohol-induced hangovers, including nausea, fatigue, and headache; Oraphyte, a nematocide; Prevorex, a liquid dietary supplement designed to help overweight individuals lose weight; purEffect, an acne treatment solution; and Talsyn-CI scar cream. It sells its products through retailers and distributors. The company was formerly known as eFoodSafety.com, Inc. and changed its name to Nuvilex Inc. in March 2009. Nuvilex Inc. is headquartered in Cherry Hill, New Jersey.

I have been hearing alot of chatter aboutt his stock for the past couple of days. I just bought back into this stock today @.028. I think this stock might have a run coming soon.

NVLX

I believe this might be worth looking into

Might be a good opportunity as of now is on the dip

RSI LINE @ 41.95



Im looking for positive movement



About Nuvilex, Inc.

Nuvilex, Inc. is an emerging healthcare consumer products company. The Company’s lead products include: Cinnergen™, which promotes a healthy glucose metabolism; Cinnechol™, designed to help maintain normal cholesterol levels and support normal cardiovascular function; and Infinitink®, a permanent yet more easily removable tattoo ink. The Company’s complete portfolio spans aesthetics, dermatology, environmental and nutraceutical products, all of which are designed to directly or indirectly improve human health. In March 2009, Nuvilex merged with Freedom2 Holdings, Inc., the developer of Infinitink®. In conjunction with the merger, the Company changed its name to Nuvilex, Inc. from eFoodSafety.com. Please visit http://www.nuvilex.com/ for additional information on the Company.

NVLX

I believe this might be worth looking into

Might be a good opportunity started out on the dip

As of now its on the up tick + 3.20%

RSI LINE @ 44.55

Showing positive signs

Keep an eye on it

Super Hot Stock Picks.

Super Stock Picker

Nuvilex, Inc. Announces that Legacy Biotechnologies' Reme-Flu with Syn-X9 Formulation Receives FDA National Drug Code Number.
Legacy Biotechnologies is now Preparing for Reme-Flu™ Market Launch




Buzz up! 0 Print..Companies:Nuvilex, Inc..Related Quotes
Symbol Price Change
NVLX.OB 0.03 0.00


{"s" : "nvlx.ob","k" : "c10,l10,p20,t10","o" : "","j" : ""} Press Release Source: Nuvilex, Inc. On Tuesday February 2, 2010, 4:15 pm EST
CHERRY HILL, N.J.--(BUSINESS WIRE)--Nuvilex, Inc. (OTC Bulletin Board: NVLX - News), announces today that Legacy Biotechnologies, Inc., its joint venture partner in Reme-Flu™, has received its National Drug Code numbers (50107-100-00, 50107-200-00, and 50107-300-00), from the Food and Drug Administration (FDA) for its homeopathic flu remedy. A National Drug Code (NDC) is a universal identifier of any product that is to be marketed as a drug for human use within the United States. The Drug Listing Act of 1972 states that all registered drug establishments must provide to the FDA a current list of all drugs manufactured, prepared, propagated, compounded, or processed by the establishment for commercial distribution.

As a registered homeopathic medicine, Reme-Flu™ is intended for use at the onset of flu or flu-like symptoms and contains ingredients widely recognized to reduce and/or shorten flu or flu-like symptoms. Legacy Biotechnologies’ Syn-X9™ formulation enhances the body’s utilization of Reme-Flu's™ active ingredients.

With the issuance of the NDC for Reme-Flu™, Legacy Biotechnologies is now preparing to manufacture, market and sell Reme-Flu™ for the spring 2010 flu season. Further details on Legacy’s marketing plans will be forthcoming.

“Legacy Biotechnologies has undertaken the appropriate and necessary steps to register Reme-Flu™ with the FDA insuring that Reme-Flu™, its labeling and packaging meet FDA standards for homeopathic remedies,” stated Martin Schmieg, Chairman and CEO of Nuvilex, Inc. “The registration process for Reme-Flu™ was exacting and time consuming, but was necessary in order to ensure that Reme-Flu™ could legally enter the marketplace. We greatly appreciate Legacy Biotechnologies’ building, registering and launching Reme-Flu™ with a commitment to quality, performance and customer satisfaction.”

According to the FDA Code of Federal Regulations, registration of a drug establishment or drug wholesaler, or assignments of a registration number, or assignment of an NDC number, does not in any way denote approval of the firm or its products.

About Nuvilex, Inc.

Nuvilex, Inc. is an emerging healthcare consumer products company. The Company’s lead products include: Cinnergen™, which promotes a healthy glucose metabolism; Cinnechol™, designed to help maintain normal cholesterol levels and support normal cardiovascular function; and Infinitink®, a permanent yet more easily removable tattoo ink. The Company’s complete portfolio spans aesthetics, dermatology, environmental and nutraceutical products, all of which are designed to directly or indirectly improve human health. In March 2009, Nuvilex merged with Freedom2 Holdings, Inc., the developer of Infinitink®. In conjunction with the merger, the Company changed its name to Nuvilex, Inc. from eFoodSafety.com. Please visit Nuvilex for additional information on the Company.

About Legacy Biotechnologies, Inc.

Legacy Biotechnologies, Inc. is an independent, privately-owned firm specializing in the research and development of nutriceutical and cosmeceutical formulations. They specialize in creating innovative and cutting-edge compounds that address all facets of health. Its president, Steve Kushner, has been working in this field for over 26 years and has created several original formulas that have been marketed both on a national basis and abroad. Mr. Kushner's experience allows Legacy Biotechnologies, Inc. to excel at all phases of the health and nutrition industry. In addition to research and development, Legacy Biotechnologies, Inc. is also well-versed in the manufacturing process, procurement of raw materials, creation of promotional material, and marketing of products.

Safe Harbor Statement

Statements contained in this presentation that are not strictly historical are "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities and Exchange Act of 1934. The forward-looking statements are made based on information available as of the date hereof, and the Company assumes no obligation to update such forward-looking statements. Forward-looking statements are sometimes identified by words such as "intends", "anticipates", "believes", "expects", and "hopes" and involve a number of risks and uncertainties that could cause the Company's actual results to differ materially from projected results. All parties are cautioned that such forward-looking statements involve risks and uncertainties that could cause the Company's actual results to differ materially from those in these forward-looking statements. Such risks and uncertainties include but are not limited to demand for the Company's products and services, the planned share exchange with Freedom2 Holdings, Inc., our ability to secure additional financing, and other factors that may be more fully described in reports to shareholders and periodic filings with the Securities and Exchange Commission.


Contact:
Nuvilex, Inc.Blair Barnes, 856-354-0707Email: bbarnes@nuvilex.comorMarmel Communications, LLCMarlin Molinaro, 702-434-8692Email: mmolinarofc@aol.com

NVLX. Company came out with news after the close yesterday. Looked at the charts and see a golden cross has formed. There is little resistance holdingus back from being back up to .042 This should run during power hour today and the rest of the

Nuvilex, Inc. (Nuvilex), formerly eFoodSafety.com, Inc., is a holding company operating through its wholly-owned subsidiaries and is dedicated in bringing to market products designed to improve the health and well-being. Nuvilex manufactures Cinnergen, Cinnechol, Infinitink and Talysn. Nuvilex markets its products both directly and through wholesale and retail distribution partners. It is also engaged in the research and development of Oraphyte, a non-toxic, biodegradable nematocide for use on turfgrass and crops, as well as Citroxin, a multi-use germicidal composition with anti-viral properties. The Company engages seven full or part-time researchers. In July 2009, the Company commenced marketing its Last Shot Hangover Remedy product.


CHECK OUT THE COMPANY WEBSITE======>Nuvilex